Evidence map›Paper›PMID 38717698›Full record

ArticleHeart and vessels2024

Plasma microRNA-143 and microRNA-145 levels are elevated in patients with left ventricular dysfunction.

Hirotaka Murase, Shingo Minatoguchi, Kazuki Heishima, Shinji Yasuda, Atsushi Satake, Ryo Yoshizumi, Hisaaki Komaki, Shinya Baba, Shinsuke Ojio, Toshiki Tanaka and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heart and vessels, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Hirotaka MuraseDepartment of Cardiology, Gifu Municipal Hospital, 7-1 Kashimachou, Gifu, 500-8513, Japan.
Shingo MinatoguchiDepartment of Cardiology, Gifu University Graduate School of Medicine, Gifu, Japan.
Kazuki HeishimaUnited Graduate School of Drug Discovery and Medical Information Science, Gifu University, Gifu, Japan.
Shinji YasudaDepartment of Cardiology, Gifu Municipal Hospital, 7-1 Kashimachou, Gifu, 500-8513, Japan.
Atsushi SatakeDepartment of Cardiology, Gifu Municipal Hospital, 7-1 Kashimachou, Gifu, 500-8513, Japan.
Ryo YoshizumiDepartment of Cardiology, Gifu Municipal Hospital, 7-1 Kashimachou, Gifu, 500-8513, Japan.
Hisaaki KomakiDepartment of Cardiology, Gifu Municipal Hospital, 7-1 Kashimachou, Gifu, 500-8513, Japan.
Shinya BabaDepartment of Cardiology, Gifu Municipal Hospital, 7-1 Kashimachou, Gifu, 500-8513, Japan.
Shinsuke OjioDepartment of Cardiology, Gifu Municipal Hospital, 7-1 Kashimachou, Gifu, 500-8513, Japan.
Toshiki TanakaDepartment of Cardiology, Gifu University Graduate School of Medicine, Gifu, Japan.
Yukihiro AkaoUnited Graduate School of Drug Discovery and Medical Information Science, Gifu University, Gifu, Japan.
Shinya MinatoguchiDepartment of Cardiology, Gifu Municipal Hospital, 7-1 Kashimachou, Gifu, 500-8513, Japan. minatos@gifu-u.ac.jp.
Hiroyuki OkuraDepartment of Cardiology, Gifu University Graduate School of Medicine, Gifu, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNA(miR)-143 and miR-145 are mainly expressed in vascular smooth muscle cells. However, the relationship between plasma miR-143 or miR-145 levels and the left ventricular (LV) function in patients with heart diseases remains unclear. Blood samples were taken from the antecubital vein in patients with heart diseases (n = 52), such as coronary artery disease, old myocardial infarction, cardiomyopathy, and valvular heart disease, and controls without heart diseases (n = 22). We measured plasma miR-143 and -145 levels by quantitative RT-PCR using TaqMan MicroRNA Assays and THUNDERBIRD Probe qPCR Mix. Plasma BNP levels were also measured. Echocardiography was performed to measure the LV ejection fraction (LVEF) and LV dilation. Plasma miR-143 and miR-145 levels were significantly higher in patients with heart diseases than in controls, respectively. Plasma miR-143 and miR-145 levels were significantly higher in patients with LVEF < 50% than in those with LVEF ≧ 50%, respectively. Plasma miR-143 and miR-145 levels were inversely correlated with LVEF, respectively. Plasma miR-143 and miR-145 levels were positively correlated with LV end-systolic dimension, respectively. Plasma miR-143 and -145 levels were positively correlated with plasma BNP levels, respectively. Plasma BNP levels were inversely correlated with LVEF. Plasma miR-143 and miR-145 levels are elevated in patients with LV dysfunction and may counteract LV dysfunction.

Indexed as

BiomarkersEchocardiographyMicroRNAsStroke VolumeVentricular Dysfunction, LeftVentricular Function, LeftAgedCase-Control StudiesFemaleHumansMaleMiddle AgedBiomarkersMicroRNAsMIRN143 microRNA, humanMIRN145 microRNA, humanHeart diseasesLV dilationLV dysfunctionMicrorna-143microRNA-145

Identifiers

PMID38717698
PMCPMC11405439

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.